

Date Fill Needed:
 ___/___/___

Patient Information

Patient Name: _____
 Date of Birth: _____ Gender: Male or Female
 Address: _____
 City: _____ State: _____ Zip: _____
 Home Phone: _____ Work Phone: _____
 Cell Phone: _____ E-mail: _____

Please attach copy of front and back of patient's insurance card(s) if applicable

Insurance Company Name: _____
 Insurance Company Phone: _____
 Policy holder: _____
 Policy holder Employer: _____
 Relationship to Patient: _____
 Prescription Coverage ID# _____ Group# _____
 RxBIN: _____ RxPCN: _____

Prescriber Information

Hemophilia Treatment Center Affiliation: _____
 Patient's Coordinator Contact: _____
 Practice/Organization Name: _____
 Physician Name: _____
 Address: _____
 City: _____ State: _____ Zip: _____
 Phone#: _____ Fax#: _____
 DEA# _____ NPI# _____
 License#: _____ Medicaid UPIN#: _____
 Shipment Address: _____
 Attn: _____
 City: _____ State: _____ Zip: _____

If shipped to the physician's office, physician accepts on behalf of patient for administration in office

Privacy & Confidentiality of Information Notice: This communication may contain non-public, confidential, or legally privileged information intended for the sole use of the designated recipient(s). If you are not the intended recipient, or have received this communication in error, please notify the sender immediately by reply email or by telephone at the number stated above and delete all copies of this communication, including any attachments, without reading them or saving them to disk. If you are the intended recipient, you must secure the contents of this communication in accordance with all applicable state or federal requirements related to the privacy and confidentiality of information, including the HIPAA Privacy guidelines.

Clinical Information and Prescription

Primary Diagnosis

D66.0 Hemophilia A (Factor VIII deficiency) D67.0 Hemophilia B (Factor IX Deficiency)
 D68.1 Hemophilia C (Factor XI Deficiency) D68.0 von Willebrand disease; type 1 2 3
 D68.2 Hereditary Deficiency (Factor X Deficiency) D68.2 Hereditary Deficiency (Factor XIII Deficiency)
 Other: _____

Severity: Mild (>5% Activity) Moderate (1-5% activity) Severe (<1% activity)

Target Joints? No Yes: _____

Inhibitor Activity: None Historical Current: _____ B.U. Bypassing Agent Use: None Yes: _____

Patient Height: _____ Weight: _____ Date Taken: _____ Allergies: _____

Current Medications: _____

Co-Morbidities: _____

Vascular Access: Peripheral IV Port-a-cath PICC Central line Other: _____

Infusion by: Patient Caregiver Nursing Agency: _____ Other: _____

Factor VIII

Recombinant: Advate Helixate FS Kogenate FS Kovaltry
 Novoeight Nuwiq Recombinate Xyntha
Long Acting Recombinant: Adynovate Afstyla Elocbate
Plasma Derived: Hemofil M Koate DVI

Factor IX

Alprolix Alphanine SD Benefix Bebulin Idelvion
 Ixinity Mononine Profilnine SD Rebinyn Rixubis

Anti-Inhibitor Products:

Feiba VH & NF Novoseven RT Novoseven

Factor X:

Coagadex

Factor XIII:

Tretten Corifact

Antithrombotic Factor / von Willebrand Factor Complex

Alphanate Humate-P Thrombate III Wilate vonWillebrand Vonvendi

Dosing Regimen	Prophylaxis	Minor bleed	Moderate Bleed	Severe Bleed
Dose in Units (mg for Factor VII)				
Number of Doses per month to dispense				

Flush Orders:

Before Factor: NaCl 0.9% (NS) _____ ml Heparin 10u/ml _____ ml Heparin 100u/ml _____ ml

After Factor: NaCl 0.9% (NS) _____ ml Heparin 10u/ml _____ ml Heparin 100u/ml _____ ml

Supplies requested: _____

Refills Authorized: 0 1 2 3 6 mos 1 yr Other: _____

Physician Signature (no stamps): _____ Date: _____